Fes una donació

Regulació gènica en cèl·lules mare, la plasticitat i diferenciació cel·lular, i el càncer

Fes una donació

Projectes destacats

Cooperation and competition between colorectal carcinomas (CRC) and their tumor microenvironment: Validation of ZEB factors as prognostic and predictive biomarkers and therapeutic targets in CRC.

Investigador/a principal: Antonio Postigo.
Finançador: Fundació Olga Torres .

Codi: FUND.OLGATORRES_19_3.

Durada: 01/01/2020 - 31/12/2021
Validation of ZEB factors as prognostic and predictive biomarkers and therapeutic targets in CRC

Investigador/a principal: Antonio Postigo.
Finançador: Asociación Española Contra el Cáncer (AECC). .

Codi: AECC_2019.

Durada: 01/11/2019 - 31/10/2022
Validation of ZEB2 as a predictive predictive biomarker and potential therapeutic target in Duchenne muscular dystrophy

Investigador/a principal: Antonio Postigo.
Finançador: Duchenne Parent Project .

Codi: DPP-E-2018.

Durada: 16/12/2018 - 15/12/2020
Tumor-microenvironment interaction: Role of ZEB factors in the reprogramming of tumor and stromal cells and their mutual interaction

Investigador/a principal: Antonio Postigo.
Finançador: Ministerio de Economia y Competitividad (MINECO) .

Codi: SAF2017-84918-R.

Durada: 01/01/2018 - 31/12/2020
Regulation of stemness and differentiation in normal and malignant hematopoietic cells by the ZEB family of transcription factors.

Investigador/a principal: Antonio Postigo Angon.
Finançador: Leukemia Research Foundation .

Codi: INT_LeukRF_NI_14_15.

Durada: 01/07/2014 - 30/06/2016
ZEB proteins and tumor progression. Role of ZEB1 and ZEB2 in oncogenic transformation, benign-malignant transition and cancer cell proliferation and survival

Investigador/a principal: Antonio Postigo Angon.
Finançador: Fundació La Marató de TV3 .

Codi: TV3_Cancer_13.

Durada: 15/04/2014 - 31/01/2018
Identificación de perfiles de expresión génica regulados por la vía microRNA/ZEB1-ZEB2 y su papel en la capacidad invasiva y metastásica de carcinomas de mama y la respuesta al tratamiento

Investigador/a principal: Antonio Postigo Angon.
Finançador: Institut d`Investigacions Biomèdiques August Pi i Sunyer (Sede o evento); Avon Breast Cancer Crusade .

Durada: 01/09/2012 - 31/12/2020

La recerca d'aquest grup es pot dur a terme gràcies als finançadors.

Projectes destacats

Cooperation and competition between colorectal carcinomas (CRC) and their tumor microenvironment: Validation of ZEB factors as prognostic and predictive biomarkers and therapeutic targets in CRC.

Validation of ZEB factors as prognostic and predictive biomarkers and therapeutic targets in CRC

Validation of ZEB2 as a predictive predictive biomarker and potential therapeutic target in Duchenne muscular dystrophy

Tumor-microenvironment interaction: Role of ZEB factors in the reprogramming of tumor and stromal cells and their mutual interaction

Regulation of stemness and differentiation in normal and malignant hematopoietic cells by the ZEB family of transcription factors.

ZEB proteins and tumor progression. Role of ZEB1 and ZEB2 in oncogenic transformation, benign-malignant transition and cancer cell proliferation and survival

Identificación de perfiles de expresión génica regulados por la vía microRNA/ZEB1-ZEB2 y su papel en la capacidad invasiva y metastásica de carcinomas de mama y la respuesta al tratamiento

Finançadors principals